If you are diagnosed with advanced melanoma, immunotherapy may be one of the most important treatment approaches your oncology team discusses with you. These medicines work differently from chemotherapy or targeted therapy because they help your immune system recognise and attack melanoma cells more effectively.
The CheckMate 067 trial became one of the landmark studies in this area by comparing nivolumab plus ipilimumab, nivolumab alone and ipilimumab alone. Its long-term results help you understand how these treatments can affect survival, tumour response and disease control, while also showing why the risk of immune-related side effects must be considered carefully.
What Was the CheckMate 067 Trial?
CheckMate 067 was an international, randomised, double-blind Phase III trial involving adults with previously untreated, unresectable stage III or stage IV melanoma. If you are reviewing immunotherapy options, the study is important because it compared three checkpoint-inhibitor strategies within the same large trial.
A total of 945 participants were randomised to nivolumab plus ipilimumab, nivolumab alone or ipilimumab alone. The co-primary endpoints were progression-free survival and overall survival for each nivolumab-containing group compared with ipilimumab.
Why Was CheckMate 067 Important?
Before modern checkpoint inhibitors became available, advanced melanoma had far fewer effective systemic treatment options. If your melanoma could not be removed surgically or had spread to distant organs, long-term disease control was much less common than it is today.
CheckMate 067 showed that treatments containing nivolumab could improve important outcomes compared with ipilimumab alone. The study also provided long-term evidence showing that some people can remain alive many years after starting immunotherapy, changing what you and your specialist may reasonably discuss when considering treatment goals.
How Was the Trial Designed?
Participants were allocated to three treatment groups. The original combination schedule used nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every three weeks for four doses, followed by nivolumab maintenance, while the monotherapy groups received nivolumab or ipilimumab with matching placebo infusions.
The table below summarises the main groups and several important trial outcomes. You should interpret the figures as population-level results rather than predictions of exactly how your melanoma will respond.
| Trial Feature | Nivolumab + Ipilimumab | Nivolumab Alone | Ipilimumab Alone |
| Participants | 314 | 316 | 315 |
| Original regimen | Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses, then nivolumab | Nivolumab 3 mg/kg every 2 weeks | Ipilimumab 3 mg/kg every 3 weeks for 4 doses |
| Median progression-free survival | 11.5 months | 6.9 months | 2.9 months |
| Objective response rate | About 58% | About 45% | About 19% |
| Grade 3–4 treatment-related adverse events | About 59% | About 21% | About 28% |
| Median overall survival at final follow-up | 71.9 months | 36.9 months | 19.9 months |
| 10-year overall-survival rate | 43% | 37% | 19% |
What Are Immune Checkpoints?
Your immune system needs mechanisms that stop immune cells from becoming excessively active and damaging healthy tissue. Immune checkpoints are part of this regulation and help keep your immune response controlled.
Melanoma can exploit these pathways to reduce the activity of T cells that might otherwise attack the cancer. Checkpoint inhibitors block particular inhibitory signals, helping your immune system maintain a stronger anti-tumour response.
How Does Nivolumab Work?
Nivolumab is an immune checkpoint inhibitor that blocks PD-1, a protein found on activated T cells. When PD-1 interacts with its ligands, including PD-L1, your T-cell response can be suppressed.
By blocking PD-1, nivolumab can help your T cells remain active against melanoma. Your response is not guaranteed, but this mechanism has allowed some people with advanced melanoma to achieve durable disease control.
How Does Ipilimumab Work?
Ipilimumab blocks CTLA-4, another immune checkpoint involved in regulating T-cell activation. It acts at a different stage of the immune response from nivolumab.
When CTLA-4 is blocked, immune activity can increase more broadly. For you, this can strengthen the anti-tumour response, but it can also increase the chance that your immune system will attack healthy tissues and cause immune-related side effects.
Why Were Nivolumab and Ipilimumab Combined?
Because PD-1 and CTLA-4 regulate different parts of your immune response, researchers believed that blocking both checkpoints could produce greater anti-tumour activity than blocking either pathway alone. The trial showed a numerically higher response rate and longer progression-free survival with the combination than with nivolumab monotherapy.
You should also know that stronger immune activation comes with greater toxicity. Combination treatment caused substantially more severe treatment-related adverse events, so the option with the highest numerical treatment activity is not automatically the best choice for you.
What Did Progression-Free Survival Show?
Median progression-free survival was 11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab and 2.9 months with ipilimumab. This means progression or death occurred later on average in the nivolumab-containing groups than in the ipilimumab group.
These medians do not tell you how long your own melanoma will remain controlled. Some participants progressed early, while others experienced disease control lasting for years after treatment began.
What Did Overall Survival Show?
At final ten-year follow-up, median overall survival was 71.9 months with the combination, 36.9 months with nivolumab and 19.9 months with ipilimumab. Ten-year overall-survival rates were 43%, 37% and 19%, respectively.
For you, these figures show that prolonged survival is possible for a meaningful proportion of people with advanced melanoma. They should not be interpreted as proof that every long-term survivor has been cured or as a prediction of your individual life expectancy.
Research Insight
The final ten-year analysis is particularly important because it shows how durable the benefit of checkpoint inhibition can be. A substantial proportion of participants in the nivolumab-containing groups remained alive a decade after treatment started.
The same analysis also reinforces the need for careful interpretation. CheckMate 067 was designed to compare each nivolumab-containing group with ipilimumab, so numerical differences between nivolumab plus ipilimumab and nivolumab alone should not be treated as definitive proof that the combination is superior for every outcome.
What Do the Response Rates Mean?
The objective response rate was approximately 58% with nivolumab plus ipilimumab, 45% with nivolumab alone and 19% with ipilimumab alone. If your melanoma responds, scans may show partial or complete tumour shrinkage during treatment.
A response rate does not mean that every response lasts indefinitely. Your specialist will continue monitoring your scans, symptoms and general health because your melanoma may respond differently from the average participant in the trial.
Does the Combination Definitely Beat Nivolumab Alone?
No. The combination produced numerically higher response and progression-free-survival results, but the trial was not powered to establish a definitive head-to-head superiority comparison between the combination and nivolumab monotherapy.
This distinction matters when you discuss treatment. Your specialist should not select combination therapy simply because one number is higher; the potential additional activity must be balanced against a substantially greater risk of severe toxicity.
What Side Effects Can Immunotherapy Cause?
Checkpoint inhibitors increase immune activity, and this can cause your immune system to attack healthy organs as well as melanoma. You may develop inflammation affecting your skin, bowel, liver, lungs, kidneys, hormone-producing glands, eyes, nerves, muscles or heart.
Some reactions are mild, but others can become serious or life-threatening. You should report new or worsening symptoms promptly because early assessment and treatment can reduce the risk of complications.
Which Symptoms Should You Report Promptly?
You should contact your oncology team if you develop persistent or severe diarrhoea, blood in your stools, significant abdominal pain, yellowing of your skin or eyes, a new cough, breathlessness, chest pain, severe headache, confusion, unusual weakness or sudden visual changes.
You should also report excessive thirst, frequent urination, marked tiredness, dizziness, reduced urine output or a severe spreading rash. These symptoms can have many causes, but your healthcare team needs to consider immune-related toxicity when you are receiving or have recently received checkpoint inhibitors.
Can Side Effects Start After Treatment Has Stopped?
Yes. Immune-related adverse reactions can occur during treatment and may also begin after immunotherapy has been discontinued. This is why you should tell healthcare professionals that you have received checkpoint-inhibitor treatment if you become unwell later.
Your treatment may need to be paused or permanently stopped if a serious reaction develops. Depending on the organ affected, your care may include corticosteroids, hormone replacement or other specialist immunosuppressive treatment.
Why Can Hormone Problems Be Long Lasting?
Checkpoint inhibitors can cause inflammation of hormone-producing glands such as your thyroid, pituitary or adrenal glands. In some cases, the gland does not fully recover even after the immune reaction has been treated.
If this happens, you may need long-term or permanent hormone replacement. Your specialist may therefore arrange blood tests to monitor hormone levels during treatment and investigate symptoms such as unusual tiredness, dizziness, headaches or changes in weight.
How Do Specialists Choose Between Combination and Single-Agent Immunotherapy?
Your treatment choice depends on more than which group had the highest response rate in CheckMate 067. Your specialist considers your general health, performance status, other medical conditions, melanoma burden, symptoms, brain metastases and how likely you are to tolerate immune-related toxicity.
Your preferences are also important. You may value the possibility of greater treatment activity despite higher toxicity, or you may prefer a monotherapy approach if reducing the likelihood of serious adverse effects is particularly important to you.
How Is Immunotherapy Used in Current UK Practice?
For untreated stage IV or unresectable stage III melanoma, NICE recommends immunotherapy as the main systemic treatment approach when it is suitable. Nivolumab plus ipilimumab may be offered when your specialist considers the combination appropriate for you.
If combination treatment is unsuitable or unacceptable, including because of potential toxicity, NICE recommends pembrolizumab or nivolumab monotherapy. Your treatment should therefore reflect both current evidence and your individual clinical circumstances.
UK Guidance Note
NICE advises your oncology team to consider comorbidities, performance status, treatment toxicity, whether you are likely to tolerate that toxicity, symptomatic brain metastases, disease burden, rapid progression and other aspects of tumour biology when selecting systemic treatment.
This means there is no single immunotherapy choice that is correct for everyone. Your specialist should discuss the expected benefits, uncertainties and risks with you so that your treatment decision is based on a full assessment rather than one trial statistic.
What If You Have an Autoimmune Condition?
Because checkpoint inhibitors stimulate immune activity, an existing autoimmune disease can complicate treatment decisions. Your specialist may need to consider whether immunotherapy could worsen your condition and whether your current medicines affect the potential benefit or risk.
Having an autoimmune condition does not automatically lead to the same decision for every person. You may need input from other specialists so that your melanoma treatment and your underlying condition can be considered together.
Evidence Note
CheckMate 067 provides high-quality randomised Phase III evidence with exceptionally long follow-up. It demonstrated improved progression-free and overall survival for nivolumab-containing treatment compared with ipilimumab and showed that durable long-term survival is possible for some people with advanced melanoma.
You should nevertheless recognise its limitations. The study was not designed to prove definitive superiority of nivolumab plus ipilimumab over nivolumab alone, active brain metastases were excluded, and trial averages cannot predict your personal outcome or determine the most appropriate treatment for you without specialist assessment.
What If Your Melanoma Has Spread to the Brain?
Brain metastases can change your treatment plan, particularly if they are causing symptoms or require corticosteroids. Your specialist may also consider surgery, stereotactic radiotherapy or other local treatments depending on your situation.
You should know that CheckMate 067 itself excluded active brain metastases, so it does not provide complete evidence for this group. Your treatment may therefore be informed by separate melanoma brain-metastasis studies and discussion within a specialist multidisciplinary team.
Why Does Your BRAF Status Still Matter?
Checkpoint inhibitors can be used whether your melanoma is BRAF-mutant or BRAF-wild type, but a BRAF V600 mutation gives you additional targeted-therapy options. Your specialist may therefore consider both immunotherapy and BRAF–MEK targeted treatment if your tumour has an actionable mutation.
Your BRAF result does not automatically decide which treatment you should receive first. Disease speed, symptoms, overall health, brain involvement and the likely benefits and risks of each approach all matter.
Clinical Tip
If combination immunotherapy is recommended, ask your specialist what additional benefit they hope it will provide for you compared with anti-PD-1 monotherapy. You should also ask how the higher risk of severe immune-related toxicity affects the recommendation in your particular situation.
Before treatment starts, make sure you know which symptoms require urgent contact and how to reach your oncology team outside routine appointments. Having this information can help you respond quickly if a new immune-related problem develops.
Why Is Long-Term Follow-Up Important?
Even when your melanoma responds well, your healthcare team needs to continue assessing disease control and your general health. Follow-up may include scans, clinical review and discussion of symptoms depending on your treatment history and current condition.
Long-term follow-up is also important because some immune-related effects may continue or appear after treatment. You should continue reporting new symptoms rather than assuming that they cannot be related to immunotherapy because your infusions have ended.
What Could Future Immunotherapy Research Mean for You?
Researchers continue to study new checkpoint combinations, treatment sequences, biomarkers, cancer vaccines and cellular therapies. The aim is to improve the chance that your melanoma responds while reducing unnecessary toxicity.
Future research may also help your specialist identify more accurately who needs combination treatment and who can achieve durable control with a less toxic approach. This could make your treatment increasingly personalised rather than relying mainly on broad clinical risk factors.
Myth vs Fact
| Myth | Fact |
| CheckMate 067 proved the combination is superior to nivolumab alone in every respect | The formal statistical comparisons were each nivolumab-containing group versus ipilimumab |
| Everyone responded to immunotherapy | Response rates were about 58%, 45% and 19% in the three groups |
| Long-term survival means advanced melanoma is definitely cured | Durable survival is possible, but cure cannot be guaranteed for you |
| Combination treatment has only slightly more toxicity | Grade 3–4 treatment-related adverse events were much more common with the combination |
| Immune side effects happen only during infusions | Reactions can occur during treatment or after it has stopped |
| Immune toxicity affects only the skin or bowel | Your lungs, liver, endocrine glands, kidneys, heart, nerves, muscles and eyes can also be affected |
| Stopping treatment because of toxicity always means treatment has failed | Some people maintain disease control after stopping, although this cannot be predicted |
| CheckMate 067 included active brain metastases | Active brain metastases were excluded from the trial |
| PD-L1 testing can perfectly predict your response | Treatment selection depends on multiple clinical factors |
| Combination immunotherapy is suitable for everyone | Your disease, health, toxicity risk and preferences all influence suitability |
Key Takeaways
- CheckMate 067 showed that nivolumab-containing immunotherapy improved long-term outcomes compared with ipilimumab alone in advanced melanoma.
- You should know that the combination produced numerically greater treatment activity but also substantially more severe toxicity than nivolumab alone.
- Your treatment choice should consider your health, melanoma characteristics, brain involvement, BRAF status, toxicity risk and personal preferences.
- You should report new symptoms promptly because immune-related reactions can affect many organs and may occur even after treatment has stopped.
Frequently Asked Questions
1. What was the CheckMate 067 trial?
CheckMate 067 was a Phase III trial involving 945 adults with previously untreated unresectable stage III or stage IV melanoma. It compared nivolumab plus ipilimumab, nivolumab alone and ipilimumab alone to help your specialist understand their relative benefits and risks.
2. What are immune checkpoint inhibitors?
Immune checkpoint inhibitors block regulatory signals that can reduce your T-cell response against melanoma. By releasing these immune brakes, the medicines can help your immune system recognise and attack your cancer more effectively.
3. Which treatment had the highest response rate?
Nivolumab plus ipilimumab had the highest numerical objective response rate at about 58%, compared with about 45% for nivolumab and 19% for ipilimumab. You should not use this number alone to choose treatment because the combination also caused substantially more severe toxicity.
4. What were the ten-year survival results?
At ten years, overall-survival rates were 43% with nivolumab plus ipilimumab, 37% with nivolumab and 19% with ipilimumab. These figures show what happened across the trial groups and cannot predict your individual survival.
5. Is nivolumab plus ipilimumab definitely better than nivolumab alone?
Not definitively. The combination produced numerically higher response and progression-free-survival results, but CheckMate 067 was not powered for a definitive statistical comparison between those two groups. Your specialist must also consider your risk of serious immune-related toxicity.
6. What side effects should you report urgently?
You should report persistent diarrhoea, blood in your stools, jaundice, significant breathlessness, chest pain, severe headache, confusion, weakness, visual changes, marked thirst or a severe rash. Your oncology team can tell you which symptoms require immediate assessment.
7. Can immunotherapy side effects occur after treatment?
Yes. Immune-related reactions may begin after your treatment has finished, so you should tell healthcare professionals about your previous checkpoint-inhibitor therapy if you become unwell later.
8. Is combination immunotherapy suitable for everyone?
No. Your general health, other conditions, melanoma burden, symptoms, brain metastases and ability to tolerate toxicity all influence whether combination therapy is appropriate for you. Your preferences should also be part of the decision.
9. Does a BRAF mutation stop you from having immunotherapy?
No. If your melanoma has a BRAF V600 mutation, you may still receive immunotherapy, while the mutation also creates targeted-therapy options. Your specialist will compare these approaches according to your individual clinical circumstances.
10. Why do you still need follow-up after immunotherapy?
Your healthcare team needs to monitor whether your melanoma remains controlled and whether treatment has caused ongoing or delayed immune-related effects. Continued follow-up also gives you an opportunity to discuss new symptoms, scans and future treatment decisions.
Final Thoughts: What Does CheckMate 067 Mean for You?
CheckMate 067 transformed advanced melanoma care by showing that nivolumab-containing immunotherapy can provide durable disease control and prolonged survival for a proportion of patients. Your treatment choice should still balance potential benefit against toxicity and should reflect your melanoma characteristics, overall health and personal priorities.
If you’d like to book a consultation with a dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. (2015) ‘Combined nivolumab and ipilimumab or monotherapy in untreated melanoma’, New England Journal of Medicine, 373(1), pp. 23–34. Available at: https://pubmed.ncbi.nlm.nih.gov/26027431/
- Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R. et al. (2017) ‘Overall survival with combined nivolumab and ipilimumab in advanced melanoma’, New England Journal of Medicine, 377(14), pp. 1345–1356. Available at: https://pubmed.ncbi.nlm.nih.gov/28889792/
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. (2019) ‘Five-year survival with combined nivolumab and ipilimumab in advanced melanoma’, New England Journal of Medicine, 381(16), pp. 1535–1546. Available at: https://pubmed.ncbi.nlm.nih.gov/31562797/
- Wolchok, J.D., Chiarion-Sileni, V., Rutkowski, P. et al. (2022) ‘Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma’, Journal of Clinical Oncology, 40(2), pp. 127–137. Available at: https://pubmed.ncbi.nlm.nih.gov/34818112/
- Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R. et al. (2025) ‘Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma’, New England Journal of Medicine, 392(1), pp. 11–22. Available at: https://pubmed.ncbi.nlm.nih.gov/39282897/
- NICE (2022) ‘Melanoma: assessment and management (NG14)’. Available at: https://www.nice.org.uk/guidance/ng14/chapter/recommendations
- Electronic Medicines Compendium (2026) ‘OPDIVO 10 mg/mL concentrate for solution for infusion – Summary of Product Characteristics’. Available at: https://www.medicines.org.uk/emc/product/6888/smpc